ARTICLE | Clinical News
Amatuximab regulatory update
February 10, 2014 8:00 AM UTC
The European Commission granted Orphan Drug designation for Eisai's amatuximab to treat malignant pleural mesothelioma (MPM). The IgG1 antibody against glycoprotein-9 ( GP-9; CD42a) is in Phase II ...